截至发稿，马毅累计任职时间11年159天，现任基金资产总规模60.63亿元，任职期间最佳基金回报 44.58%， 任职期间最差基金回报-0.61%。 从基金十大重仓股角度 数据显示，同泰基金旗下1只基金重仓一品红。同泰大健康主题混合A（011002）二季度减持1.91万股， 持有股数2.69万股，占基金净值比例为5.99%，位居第二大重仓股。根据测算，今日浮亏损失约9.41万 元。 同泰大健康主题混合A（011002）成立日期2021年4月8日，最新规模618.23万。今年以来收益51.96%， 同类排名304/8192；近一年收益60.49%，同类排名1079/7956；成立以来亏损37.65%。 同泰大健康主题混合A（011002）基金经理为马毅、麦健沛。 8月22日，一品红跌5.02%，截至发稿，报66.22元/股，成交3.66亿元，换手率1.30%，总市值299.11亿 元。 资料显示，一品红药业集团股份有限公司位于广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大 厦15-19层，成立日期2002年2月4日，上市日期2017年11月16日，公司主营业务涉及自有药品的研发、 生产和销售及代理药品的销 ...

Core Viewpoint - The company Yipinhong reported a significant loss in the first half of the year, despite a previous surge in stock price driven by the anticipation of a new gout treatment drug. The company also voluntarily disclosed progress on the drug's clinical trials shortly after the financial report was released [1][3]. Financial Performance - In the first half of 2025, Yipinhong achieved revenue of 584 million yuan, a year-on-year decline of 36% [3]. - The net profit attributable to the parent company was -73.54 million yuan, compared to a profit of 46.46 million yuan in the same period last year. The adjusted net loss, excluding non-recurring items, expanded to 108 million yuan [3]. - The company's sales expenses for the first half of 2025 amounted to 208 million yuan, accounting for 35.6% of revenue, showing a rising trend compared to 34% in the first quarter of 2025 and 34.86% for the entire previous year [3]. Drug Development Progress - Yipinhong announced that the global Phase III clinical trial for its gout drug AR882 has completed the enrollment of all participants. This drug is developed in collaboration with Arthrosi and aims to treat gout by inhibiting uric acid reabsorption [5]. - The clinical trial consists of two independent parallel studies, REDUCE 1 and REDUCE 2, with the completion of participant enrollment marking a significant milestone for the drug's development [5]. Company Overview - Yipinhong is a biopharmaceutical company that integrates drug research and development, production, and sales, focusing on pediatric and chronic disease medications. The company was listed on the Growth Enterprise Market in 2017 [6]. Market Capitalization - As of August 21, Yipinhong's market capitalization exceeded 30 billion yuan, reaching 31.49 billion yuan [7].

（文章来源：证券日报） 证券日报网讯 8月21日晚间，一品红发布公告称，公司第四届董事会第十一次会议审议通过了《关于的 议案》。 ...

证券日报网讯 8月21日晚间，一品红发布公告称，公司第四届监事会第十次会议审议通过了《关于的议 案》。 （文章来源：证券日报） ...

针对营收下滑的原因，一品红表示，主要是受市场环境变化影响销售不及预期所致。 （文章来源：北京商报） 8月21日晚间，一品红（300723）披露2025年半年报显示，公司上半年实现营业收入5.84亿元，同比下 降36.02%；归属净利润为-7354.22万元，同比由盈转亏。 ...

Growth - Teva Pharmaceutical reported a net profit of 38.01 million yuan in the first half of the year, a year-on-year increase of 1313.23% [1] - Qianfang Technology achieved a net profit of 170 million yuan, up 1287.12% year-on-year [1] - Tianyu Digital Science and Technology recorded a net profit of 23.62 million yuan, reflecting a 453.67% increase [1] - Suzhou Gude reported a net profit of 43.70 million yuan, up 310.28% year-on-year [1] - Sainuo Medical achieved a net profit of 13.84 million yuan, an increase of 296.54% [1] - Runfeng Co., Ltd. reported a net profit of 556 million yuan, up 205.62% year-on-year [1] - Guodian Nanzi achieved a net profit of 159 million yuan, reflecting a 197.03% increase [1] - Ruijie Networks reported a net profit of 452 million yuan, up 194% year-on-year [1] - Zhongjing Technology achieved a net profit of 25.74 million yuan, an increase of 144.05% [1] - China National Materials Technology reported a net profit of 999 million yuan, up 114.92% year-on-year [1] - Lante Optics achieved a net profit of 103 million yuan, reflecting a 110.27% increase [1] - Yidao Information reported a net profit of 11.41 million yuan, up 96.02% year-on-year [1] - Qianzhao Optoelectronics achieved a net profit of 69.23 million yuan, an increase of 88.04% [1] - Ruile New Materials reported a net profit of 166 million yuan, up 74.22% year-on-year [1] - Lvtian Machinery achieved a net profit of 140 million yuan, reflecting a 64.36% increase [1] - Mega Chip Color reported a net profit of 110 million yuan, up 48.83% year-on-year [1] - Jiaojian Co., Ltd. achieved a net profit of 113 million yuan, an increase of 48.66% [1] - Huhua Electronics reported a net profit of 1.683 billion yuan, up 47.50% year-on-year [1] - Sany Heavy Industry achieved a net profit of 5.216 billion yuan, reflecting a 46% increase [1] - Goodix Technology reported a net profit of 431 million yuan, up 35.74% year-on-year [1] - Allwinner Technology achieved a net profit of 161 million yuan, an increase of 35.36% [1] - Bichu Electronics reported a net profit of 640 million yuan, up 30.32% year-on-year [1] - Ganneng Co., Ltd. achieved a net profit of 438 million yuan, reflecting a 29.39% increase [1] - Weigao Medical reported a net profit of 492 million yuan, up 28.07% year-on-year [1] - GoerTek achieved a net profit of 1.417 billion yuan, reflecting a 15.65% increase [1] - Huason Pharmaceutical reported a net profit of 53.95 million yuan, up 14.27% year-on-year [1] - Gaoxin Development achieved a net profit of 66.92 million yuan, an increase of 14.06% [1] - Shanghai Jahwa reported a net profit of 266 million yuan, up 11.66% year-on-year [1] Stable Growth - Hangcha Group reported a net profit of 1.121 billion yuan, reflecting an increase of 11.38% year-on-year [2] - Dong'e Ejiao achieved a net profit of 818 million yuan, up 10.74% [2] - Beikong Technology reported a net profit of 54.31 million yuan, an increase of 10.59% [2] - Hongxin Electronics achieved a net profit of 53.99 million yuan, up 9.85% year-on-year [2] - Huace Testing reported a net profit of 467 million yuan, reflecting a 7.03% increase [2] - Samsung Medical achieved a net profit of 1.230 billion yuan, up 6.93% year-on-year [2] - Jiangzhong Pharmaceutical reported a net profit of 522 million yuan, reflecting a 5.80% increase [2] - Hualing Cable achieved a net profit of 63.64 million yuan, up 4.74% year-on-year [2] - Kuaijishan reported a net profit of 93.88 million yuan, reflecting a 3.41% increase [2] - Laishen Tongling achieved a net profit of 60.61 million yuan, turning from loss to profit [2] - Yunnan Geology reported a net profit of 22.15 million yuan, turning from loss to profit [2] - Shandong Steel achieved a net profit of 1.253 million yuan, turning from loss to profit [2] Decline and Loss - Zhongtian Rocket reported a net profit of 394,460 yuan, a year-on-year decrease of 80.74% [2] - Liuhua Co., Ltd. achieved a net profit of 344,280 yuan, down 78.01% year-on-year [2] - Qiaqia Food reported a net profit of 886.42 million yuan, a decrease of 73.68% [2] - Hangjin Technology achieved a net profit of 1.372 million yuan, down 58.38% year-on-year [2] - Taiping Bird reported a net profit of 7.771 million yuan, a decrease of 54.61% [2] - Canadian Solar reported a net profit of 731 million yuan, down 41.01% year-on-year [2] - Sinopec achieved a net profit of 21.483 billion yuan, a decrease of 39.8% [2] - Fulejia reported a net profit of 230 million yuan, down 32.54% year-on-year [2] - Palin Bio reported a net profit of 236 million yuan, down 27.89% [2] - Yiwei Lithium Energy achieved a net profit of 1.605 billion yuan, down 24.9% year-on-year [2] - Jinguang Electric reported a net profit of 42.34 million yuan, down 17.16% [2] - Hexing Co., Ltd. achieved a net profit of 107 million yuan, down 16.98% year-on-year [2] - Electric Investment Production and Financing reported a net profit of 459 million yuan, down 13.41% [2] - Tiantan Biological achieved a net profit of 633 million yuan, down 12.88% year-on-year [2] - Huali Group reported a net profit of 1.671 billion yuan, down 11.06% [2] - Zhongyou Engineering achieved a net profit of 470 million yuan, down 10.87% year-on-year [2] Further Losses - Chongda Technology reported a net profit of 222 million yuan, down 6.19% year-on-year [3] - Xinhua Department Store achieved a net profit of 86.01 million yuan, down 2.52% [3] - Zhuosheng Micro reported a net loss of 147 million yuan, turning from profit to loss [3] - Penghui Energy reported a net loss of 88.23 million yuan, turning from profit to loss [3] - Yipin Hong reported a net loss of 73.54 million yuan, turning from profit to loss [3] - Zhongbing Hongjian reported a net loss of 40.71 million yuan, turning from profit to loss [3] - Sanwei Xinan reported a net loss of 29.39 million yuan, turning from profit to loss [3] - Anyuan Coal reported a net loss of 290 million yuan [3] - Keda Xunfei reported a net loss of 239 million yuan [3] - Jishi Media reported a net loss of 23.2 million yuan [3] - Nanjing Chemical Fiber reported a net loss of 88.93 million yuan [3] - Guangsheng Tang reported a net loss of 66.69 million yuan [3] - Chutian Long reported a net loss of 39.77 million yuan [3]

针对营收下滑的原因，一品红表示，主要是受市场环境变化影响销售不及预期所致。 北京商报讯（记者 丁宁）8月21日晚间，一品红（300723）披露2025年半年报显示，公司上半年实现营 业收入5.84亿元，同比下降36.02%；归属净利润为-7354.22万元，同比由盈转亏。 ...

Core Insights - Yipinhong Pharmaceutical Group Co., Ltd. reported a steady development in the first half of 2025, focusing on children's medicine, chronic disease drugs, and innovative drugs [1] - The company achieved a revenue of 584 million yuan and a net profit attributable to shareholders of -73.54 million yuan in the first half of 2025 [1] - Total assets reached 4.981 billion yuan, reflecting a 13.1% increase compared to the beginning of the period [1] Financial Performance - Revenue for the first half of 2025 was 584 million yuan [1] - Net profit attributable to shareholders was -73.54 million yuan [1] - Total assets as of June 30, 2025, were 4.981 billion yuan, up 13.1% from the start of the year [1] R&D and Product Development - The company invested approximately 94.201 million yuan in R&D, accounting for 16.14% of total revenue [1] - A total of 10 new registration certificates were obtained, maintaining a leading position among pharmaceutical companies [1] - The company introduced 2 CMO projects and 1 equity investment project during the reporting period [1] Innovative Drug Progress - The innovative drug AR882 (Dezhuobote) is a selective URAT1 inhibitor with three indications: lowering blood uric acid for gout treatment, dissolving gout stones, and treating chronic kidney disease [2] - The global pivotal Phase III REDUCE 2 trial completed patient enrollment in March 2025, and the REDUCE 1 trial surpassed 50% enrollment by June 2025 [2] - The company acquired 15.25% of the equity in its subsidiary Guangzhou Ruianbo, increasing its ownership of AR882 in China to 100% [2]

Core Insights - The company Yipinhong (300723) reported a revenue of 584 million yuan and a net profit attributable to shareholders of -73.54 million yuan for the first half of 2025, indicating a focus on children's medicine, chronic disease drugs, and innovative drugs [1] - As of June 30, 2025, the company's total assets reached 4.981 billion yuan, an increase of 13.10% compared to the beginning of 2025 [1] - The company achieved significant progress in innovative drugs, obtaining 10 drug registration approvals in the first half of the year, with the global development of the innovative drug AR882 accelerating [1][2] Financial Performance - The company's revenue for the first half of 2025 was 584 million yuan, with a net loss of 73.54 million yuan [1] - Research and development investment for the first half of 2025 was approximately 94.21 million yuan, accounting for 16.14% of the company's revenue [1] Product Development - Yipinhong currently holds 200 drug registration approvals, including 87 national medical insurance varieties and 26 national basic drug varieties [2] - In the children's medicine sector, the company has 27 registration approvals covering common diseases such as respiratory, anti-infection, anti-allergy, and digestive issues [2] - In the chronic disease drug sector, there are 67 registration approvals addressing cardiovascular, urinary, and digestive system diseases [2] - The company also received 5 new product approvals in other therapeutic areas during the reporting period, expanding its product portfolio [2] Innovative Drug AR882 - AR882, developed in collaboration with Arthrosi, is a first-class innovative drug aimed at treating gout and gout stones by inhibiting uric acid reabsorption [2] - The drug's research results were presented at the 2025 European League Against Rheumatism (EULAR) conference, gaining international attention [2] - The global pivotal phase III REDUCE2 trial for AR882 has completed enrollment of all patients, while the REDUCE1 trial has surpassed 50% patient enrollment as of June 2025 [2]

Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. has completed the enrollment of all participants in the global Phase III clinical trial for AR882, a novel drug for the treatment of gout and gout stones, developed in collaboration with Arthrosi Therapeutics, Inc. [1] Group 1 - AR882 (generic name: Deuricostat) is a first-class innovative drug that acts as a selective uric acid transporter (URAT1) inhibitor, aimed at normalizing uric acid salt excretion in urine and lowering serum uric acid (sUA) levels [1] - The company indirectly holds a 22.52% stake in Arthrosi [1] - The company, through its wholly-owned subsidiary Guangzhou Ruian Bo Pharmaceutical Technology Co., Ltd., holds 100% of the marketing authorization and all commercialization rights for AR882 in the Chinese region, including mainland China, Hong Kong, Macau, and Taiwan [1]